BlossomHill Therapeutics
SAN DIEGO, CA · Biotechnology, Healthcare, Health Care · 55 employees
BlossomHill Therapeutics, Inc. is a small molecule drug discovery and development company focused on unmet medical needs in oncology and autoimmune disorders. The company is founded by renowned drug design and development scientist, J. Jean Cui, Ph.D., and biotech business veteran, Y. Peter Li, Ph.D., M.B.A. BlossomHill Therapeutics, Inc. is headquartered in San Diego, California.
Funding history
- Funding Round — $84.2M — Dec 2025
- Series series b — $100.0M — Feb 2024
- Funding Round — $88.6M — Jan 2024
- Funding Round — $71.0M — Mar 2021
- Funding Round — $2.0M — Jan 2021
Recent signals
- Dec 10, 2025: Raised $84.2M
- May 09, 2025: BlossomHill Therapeutics Appoints Jason Keyes as Chief Financial Officer
- Jan 22, 2025: Launched BlossomHill Therapeutics Doses First Cohort of Patients in Phase 1/2 Clinical Trial for BH-30643 Targeting Lung Cancer.
- Jan 06, 2025: BlossomHill Therapeutics Appoints Geoff Oxnard as Chief Medical Officer and Executive Vice President, and Ashley Preston as Senior Vice President and Head of Regulatory Affairs and Quality Assurance
- Feb 29, 2024: Raised $100.0M in Series series b
- Jan 02, 2024: Raised $88.6M
- Mar 01, 2021: Raised $71.0M
- Jan 11, 2021: Raised $2.0M
See plans & pricing → Track BlossomHill Therapeutics’s funding, hiring, and signals — with verified contacts — on Fundz.